ANAPTYSBIO, INC Net Income (Loss) Attributable to Parent in USD from 2015 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Anaptysbio, Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to Q3 2025.
  • Anaptysbio, Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was $15.1M.
  • Anaptysbio, Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$84.6M, a 48.9% increase year-over-year.
  • Anaptysbio, Inc annual Net Income (Loss) Attributable to Parent for 2024 was -$145M, a 11.2% increase from 2023.
  • Anaptysbio, Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$164M, a 27.1% decline from 2022.
  • Anaptysbio, Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$129M, a 123% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

ANAPTYSBIO, INC Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$84.6M $15.1M +$48M Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 -$133M -$38.6M +$8.03M +17.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-04
Q1 2025 -$141M -$39.3M +$4.61M +10.5% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-04
Q4 2024 -$145M -$21.8M +$20.4M +48.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 -$166M -$32.9M +$4.46M +11.9% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 -$170M -$46.7M -$6.82M -17.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-04
Q1 2024 -$163M -$43.9M +$319K +0.72% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-04
Q4 2023 -$164M -$42.2M -$15.8M -59.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 -$148M -$37.3M -$3.81M -11.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$144M -$39.8M -$7.29M -22.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 -$137M -$44.3M -$8M -22.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$129M -$26.4M +$6.13M +18.8% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 -$135M -$33.5M -$26.8M -403% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$108M -$32.6M -$32.1M -7488% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 -$75.9M -$36.3M -$18.1M -99.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 -$57.8M -$32.5M -$66.2M -197% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-11
Q3 2021 $8.39M -$6.67M +$17.1M +72% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$8.71M -$429K +$21.1M +98% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$29.8M -$18.2M -$9.9M -120% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$19.9M $33.6M +$53.9M Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 -$73.8M -$23.8M +$7.27M +23.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$81.1M -$21.5M +$2.41M +10.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$83.5M -$8.26M +$13.8M +62.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$97.3M -$20.3M -$3.27M -19.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-07
Q3 2019 -$94.1M -$31M -$15.1M -94.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$79M -$24M -$10.3M -76% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-04
Q1 2019 -$68.6M -$22.1M -$6.99M -46.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-04
Q4 2018 -$61.7M -$17M -$10.1M -148% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$51.5M -$16M -$6.87M -75.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$44.7M -$13.6M -$10.9M -407% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-08
Q1 2018 -$33.7M -$15.1M -$3.65M -31.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-08
Q4 2017 -$30.1M -$6.86M -$2.28M -49.9% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-02
Q3 2017 -$27.8M -$9.09M -$7.98M -715% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$19.8M -$2.68M -$5.01M -216% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$14.8M -$11.4M -$10.5M -1188% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 -$4.26M -$4.58M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 -$1.12M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $2.32M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 -$888K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12

ANAPTYSBIO, INC Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$145M +$18.4M +11.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 -$164M -$34.9M -27.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 -$129M -$70.9M -123% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 -$57.8M -$37.9M -190% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-11
2020 -$19.9M +$77.4M +79.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$97.3M -$35.7M -57.9% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-07
2018 -$61.7M -$31.6M -105% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$30.1M -$25.8M -606% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 -$4.26M +$1.15M +21.2% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$5.41M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.